Immunovant, Inc. Common Stock (IMVT)
Immunovant, Inc. is a biotechnology company focused on developing and commercializing therapies for autoimmune diseases and other immune-mediated disorders. The company primarily targets B-cell mediated conditions, aiming to provide innovative treatments through its antibody modulation platform.
Company News
Law firm Kahn Swick & Foti, LLC has initiated an investigation into Century Aluminum Company, examining potential breaches of fiduciary duties or violations of state/federal laws by its officers and directors.
Immunovant's stock gained 11% after reporting positive results from a proof-of-concept study for batoclimab, an investigational drug targeting Grave's disease. The study showed 17 out of 21 patients maintained normal thyroid function six months after treatment.
Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
